For & Against
What's Next
Three catalysts converge in a single month: the NEC MDL bellwether trial begins in July 2026, and H1 2026 results land on July 29. That collision — litigation exposure meeting earnings disclosure — is the event the market will watch above all others in the next six months. Everything else is secondary.
The July cluster is what matters. The NEC trial and H1 results land within days of each other, meaning the half-year report could land with an IAS 37 provision already required. The Q1 2026 print (+1.3% LFL) was benign but thin — it keeps guidance intact without proving the 4–5% LFL target that underpins the re-rating thesis. There is no real catalyst for the bull case between now and July unless Reckitt announces an IFCN US sale first.
For / Against / My View
For
The bull case rests on a cheap multiple on durable brands, a cleanup in visible execution, and a FCF yield that exceeds most alternatives in the sector. The three sharpest points:
12% FCF yield with a proven £2bn annual floor
The core business delivered £1.8–2.3bn in free cash flow every single year from 2020–2024 — through a pandemic surge, inflationary shock, and major IFCN operational disruption. At 2,406p (£17.1bn market cap), that is a 12%+ FCF yield with a 7.3% cash-covered dividend collected while waiting for the catalyst. No FTSE 100 consumer staples peer offers this combination. Evidence: FY2024 FCF £2,089M; FCF never below £1,836M across five years; dividend covered 1.7x by FCF. OCF/revenue ran 18–19% consistently with no evidence of working capital manipulation.
Haleon-quality margins at a 45% Haleon discount
Reckitt's adjusted EBITDA margin (23.3%) is nearly identical to Haleon's (22.5%) — the closest structural peer, also a defensive OTC health/hygiene franchise — yet trades at 7.4x EV/EBITDA versus Haleon's 13.5x. Gross margins have held at 57.8–59.8% for five straight years. The multiple gap is entirely IFCN and NEC, not brand deterioration. Every £1 of EBITDA at Reckitt is priced at £7.40 versus Haleon's £13.50 for economically equivalent earnings. Evidence: Peer scatter showing Reckitt as clear valuation outlier at same margin as Haleon. 5-year mean EV/EBITDA 11.3x vs current 7.4x — 35% below Reckitt's own history.
Portfolio cleanup is executing, not just planned
Essential Home (Harpic, Air Wick, Vanish) was divested on 31 December 2025 with proceeds returned to shareholders in February 2026. IFCN US — the primary discount driver — is under active sale process. The balance sheet has already absorbed £6.3bn in goodwill impairments; future write-downs are mechanically smaller. An IFCN disposal at any reasonable valuation removes the segment that caused every margin miss and management credibility hit since 2022. The restructuring is not a promise; it is in motion. Evidence: Essential Home divestiture December 2025 to Advent International confirmed. IFCN strategic review active. Disposal brings leverage from ~1.9x toward ~1.0x net debt/EBITDA.
July 2026 MDL trial is a zero-provision balance-sheet bomb
The NEC MDL bellwether trial begins July 2026. A $60M verdict was already returned against Reckitt's subsidiary in March 2024; Abbott's comparable Similac litigation produced a $495M award. Thousands of filed cases remain. Analyst estimates of total Reckitt exposure range £1bn (RBC) to £5bn (Jefferies), with zero — literally zero — recognised provision on the FY2024 balance sheet. Under IAS 37, the "probable obligation" threshold is credibly at or past the recognition point. A £2bn provision crystallising in the next 12–18 months would consume one full year of FCF, push net debt from 1.9x to approximately 2.6x adj EBITDA, and almost certainly force a dividend cut on a stock whose primary investment case is a 7.3% yield. Evidence: Zero quantified provision; $60M verdict 2024; MDL trial July 2026; analyst range £1–5bn; IAS 37 threshold arguably met. Management has explicitly declined to disclose the provision held against NEC litigation.
Five years of zero revenue growth invalidates the re-rating thesis
The re-rating story requires Core Reckitt to grow at 4–5% LFL post-IFCN disposal. Revenue has been range-bound at £13–14.5bn since 2020 with zero compound growth. In FY2024, group LFL was −0.5% against guidance of 2–4%. The FY2024 adj EBITDA margin of 23.3% missed management's own ~26% guidance by 270bp. The FY2025 margin guidance of 23–24% does not project a recovery — it downgrades the structural margin floor. FY2025 Core Reckitt delivered +5.2% — but Q1 2026 has already slipped to +1.3%, raising the question of whether 2025 was structural recovery or seasonal catch-up. Evidence: FY2024 LFL guided "2–4%", delivered "−0.5%", missed. FY2024 EBITDA margin guided "~26% broadly stable", delivered "23.3%", missed. Management credibility: two consecutive guidance misses on both revenue and margins; Q1 2026 LFL +1.3%.
Balance sheet cannot absorb NEC without a dividend cut
FCF coverage of total capital returns compressed from 1.32x (FY2023) to 1.20x (FY2024) as FCF held flat while dividends drifted higher. Net debt has risen from £5.3bn to £5.9bn, putting leverage at 1.9x — the top of management's stated 1.5–2.0x target range. Note: the Essential Home disposal has pushed leverage toward ~2.5x by H1-2026, because proceeds were returned to shareholders rather than used to reduce debt. A £1bn NEC cash settlement — the bottom of the analyst range — lifts net debt to approximately £6.9bn and leverage to ~2.2x adj EBITDA, breaching management's own target. The dividend was already cut 4.4% in FY2024 (182.7p to 174.6p) while the NEC exposure was growing and remaining undisclosed. Evidence: Net debt/EBITDA has risen from 1.4x (FY2020) to 1.9x (FY2024), approaching the top of the 1.5–2.0x target. Capital returns covered by FCF at approximately 1.20x — any NEC cash settlement narrows the buffer further. Dividend cut while management pay was unchanged.
Bull Price Target (p)
Bear Downside Target (p)
Bull: 4,000p within 12–18 months, primary catalyst being IFCN disposal with NEC liability transferred to buyer. Methodology: 10x EV/EBITDA on FY2025E adj EBITDA of ~£3.25bn, less post-disposal net debt of ~£3.9bn.
Bear: 1,500p within 12–18 months, primary trigger being an adverse MDL bellwether NEC verdict in July 2026 forcing an IAS 37 provision. Methodology: 5.5x FY2025E adj EBITDA less net debt of £5.9bn plus a £2bn NEC provision crystallised.
Against
See the three Against cards above. The bear thesis centres on a single quantifiable event — the July 2026 MDL trial — whose outcome management has refused to provision for across three consecutive years.
The Tensions
1. FCF yield: genuine floor or provision-contingent mirage?
Bull says the £2.1bn annual FCF creates a 12%+ yield and covers the dividend at 1.7x, providing real compensation while the corporate actions play out. Bear says that same £2.1bn is a one-year reserve against a liability that analysts estimate at £1–5bn — meaning the "floor" is only a floor if the NEC liability stays uncrystallised. Both sides cite the same number: FY2024 FCF of £2,089M. The reading differs entirely on whether a provision is imminent. This resolves on the July 2026 MDL bellwether verdict and Reckitt's H1 2026 response: an adverse verdict that triggers an IAS 37 recognition event collapses the FCF buffer and dividend cover simultaneously; an outright dismissal or small settlement validates the bull's yield framing.
2. Disposal programme: de-leveraging catalyst or leveraging trap?
Bull says the IFCN US disposal reduces net debt from 1.9x to ~1.0x EBITDA and forces a multiple re-rate toward 10–11x. Bear says the completed Essential Home disposal has already pushed leverage toward ~2.5x by H1-2026, because £1.6bn in proceeds were returned to shareholders via special dividend rather than applied to debt — and an IFCN sale below carrying value triggers further impairments while leaving stranded costs. Both sides cite the divestiture programme and the net debt/EBITDA trajectory. This resolves on the H1 2026 results (July 29): if leverage is materially above 2.0x despite the disposals, and no IFCN deal terms are disclosed, the de-leveraging thesis loses its near-term anchor. If an IFCN announcement includes explicit NEC indemnification from the buyer, the Bull wins this tension outright.
3. Core growth: structural recovery or 2025 anomaly?
Bull's re-rating thesis implicitly requires Core Reckitt to sustain 4–5% LFL once IFCN is removed. Bear cited FY2024's −0.5% group LFL miss as proof the capability does not exist; Hygiene was +1.2% and Health +2.8% — below the medium-term target. FY2025 delivered +5.2% Core Reckitt growth (ahead of management's "above 4%" guidance), appearing to vindicate the bull. But Q1 2026 has already decelerated to +1.3%, with weak cold/flu season and European softness. Both sides cite the core LFL growth rate; the disagreement is whether the single good year (2025) was structural or seasonal. This resolves over the Q2–Q3 2026 data: sustained LFL of 3%+ through a second consecutive year validates the re-rating multiple; a second miss below 2% confirms the bear's structural growth ceiling.
My View
The Against side is heavier, and Tension 1 — the NEC FCF absorption question — is the deciding factor. The bull case is not dishonest: the brand portfolio is real, the FCF is real, FY2025 core growth of 5.2% is a genuine positive, and the Essential Home disposal actually executed. But the July 2026 MDL trial creates a near-term binary that none of those positives can offset if it goes adversely: a £2bn provision forced by an adverse verdict wipes out a year of FCF, pushes leverage well above the 2.0x covenant ceiling, and makes a dividend cut probable on a stock that is largely owned for its yield. Management's three-year silence on the provision size — structurally incentivised by a compensation framework tied to adjusted metrics that exclude impairments — makes it harder, not easier, to give benefit of the doubt. I'd lean cautious here: the yield is attractive in theory, but the income case rests on a litigation outcome that management has repeatedly refused to quantify. The one condition that would flip the view is a confirmed IFCN US disposal with an explicit NEC liability transfer and indemnity structure — that single announcement simultaneously removes the provision risk, de-levers the balance sheet, and validates the cleanup narrative. Until that deal is announced, the July 2026 trial is the first thing to wait through, not on.